Work Files Saved Searches
   My Account                                                  Search:   Quick/Number   Boolean   Advanced   Derwent    Help   


 The Delphion Integrated View
  Buy Now:   Buy PDF- 15pp  PDF  |   File History  |   Other choices   
  Tools:  Citation Link  |  Add to Work File:    
  View:  Expand Details   |  INPADOC   |  Jump to: 
  Go to:  Derwent  
 Email this to a friend  Email this to a friend 
       
Title: US5562907: Method to prevent side-effects and insensitivity to the therapeutic uses of toxins
[ Derwent Title ]
>> View Certificate of Correction for this publication

Country: US United States of America

View Images High
Resolution

 Low
 Resolution

 
15 pages

 
Inventor: Arnon, Stephen S.; Orinda, CA 94563

Assignee: None

Published / Filed: 1996-10-08 / 1994-06-06

Application Number: US1994000254238
IPC Code: Advanced: A61K 38/16; A61K 38/48; C07K 16/12; C07K 16/18; C07K 16/40; A61K 38/00;
Core: A61K 38/43; more...
IPC-7: A61K 39/08; A61K 39/38; C07K 16/46;

ECLA Code: A61K38/16B; A61K38/48N; C07K16/12B16; C07K16/18; C07K16/40;

U.S. Class: Current: 424/236.1; 424/130.1; 424/141.1; 424/142.1; 424/150.1; 424/164.1; 424/167.1; 424/239.1; 424/542;
Original: 424/236.1; 424/239.1; 424/542; 424/130.1; 424/141.1; 424/142.1; 424/150.1; 424/164.1; 424/167.1;

Field of Search: 424/130.1,141.1,142.1,150.1,164.1,167.1,R39.1,236.1,542

Priority Number:
1994-03-08  WO1994US0002521

Abstract: Human-derived or human-compatible antitoxins are administered is an adjunct to therapy with a toxin, such as botulinum toxin or an immunotoxin, or as an adjunct to therapy with a combination of toxins, in order to reduce or prevent endogenous production of antibodies to the toxin(s) or other unwanted side-effects.

Attorney, Agent or Firm: Morrison & Foerster ;

Primary / Asst. Examiners: Scheiner, Toni R.;

Maintenance Status: CC Certificate of Correction issued
View Certificate of Correction

INPADOC Legal Status: Show legal status actions          Buy Now: Family Legal Status Report

       
Related Applications:
Application Number Filed Patent Pub. Date  Title
US1993000062110 1993-05-14       


       
Parent Case:

REFERENCE TO RELATED APPLICATION
    This application is a continuation-in-part of U.S. patent application Ser. No. 08/062,110 filed on May 14, 1993, now abandoned. That application is incorporated by reference.

Designated Country: AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE  EP JP 

Family: Show 9 known family members
First Claim:
Show all 16 claims		 What is claimed is:     1. An improved method of providing toxin therapy to a human patient by administering an effective non-lethal dose of a toxin to a treatment site in the patient wherein the improvement comprises administering intravenously to the patient a human-derived or human-compatible antitoxin that binds specifically to the toxin in an amount and at a time sufficient to prevent toxin that fails to bind to said site from stimulating the patient's immune system to produce endogenous antitoxin antibodies.

Background / Summary: Show background / summary

Drawing Descriptions: Show drawing descriptions

Description: Show description

Forward References: Show 27 U.S. patent(s) that reference this one

       
U.S. References: Go to Result Set: All U.S. references   |  Forward references (27)   |   Backward references (4)   |   Citation Link

Buy
PDF		 Patent  Pub.Date  Inventor Assignee   Title
Buy PDF- 12pp US4341762  1982-07 Haast   Use of snake venoms for treatment of neurological and related disorders
Buy PDF- 13pp US4689299  1987-08 Inseletal  University of Rochester Human monoclonal antibodies against bacterial toxins
Buy PDF- 8pp US5053005  1991-10 Bovodic  Borodic; Gary E. Chemomodulation of curvature of the juvenile spine
Buy PDF- 9pp US5183462  1993-02 Bovodic  Associated Synapse Biologics Controlled administration of chemodenervating pharmaceuticals
       
Foreign References: None

Other Abstract Info: CHEMABS 122(06)064301U CHEMABS 125(23)299421J CHEMABS 125(23)299421J DERABS C1996-464115 DERABS C1995-006363 DERABS C1996-464115

Other References:
  • Bach et al (1993) Immunol. Today 14(9):421-424. (5 pages) Cited by 22 patents [ISI abstract]
  • Arnon (1993) In "Botolinum and Tetanus Neurotoxeus: Neurotrossnussion and Biomedical Aspects" (Das Gypto, ed.) Plenum Press, N.Y., pp. 477-482, title & publ. pages.
  • Franz et al (1993) In "Botolinum and Tetanus Neurotoxnus: Neurotrossnussion and Biomedical Aspects" (Das Gupta, ed.) Plenum Press, N.Y., pp. 473-476, title & publ. pages.
  • Frankovich et al., "Clinical trial of botulism immune globulin for infant botulism" The Western Journal of Medicine (1991) 154(1):103. (1 pages) Cited by 17 patents [ISI abstract]
  • "Clinical Use of Botulinum Toxin" Reprinted from: NIH Consens. Dev. Conf. Consens. Statement (Nov. 12-14, 1990), vol. 8, No. 8, pp. 1-20.
  • Hall et al., "Isolation of an Organism Resembling Clostridium baratiWhich Produces Type F Botulinal Toxin from an Infant with Botulism" J. Clin. Microbiol. (1985) 21(4):654-655. (2 pages)
  • Hatheway, "Bacteriology and Pathology of Neurotoigenic Clostridia" Botulinum adn Tetanus Neurotoxins: Neurotransmission and Biomedical Aspects, DasGupta, ed., Plenum Press, New York, 1993, pp. 491-502.
  • Aureli et al., "Two Cases of Type E Infant Botulism Caused by Neurotoxigenic Clostridium butyricum in Italy" J. Infect. Dis. (1986) 154(2):207-211. (5 pages) Cited by 4 patents
  • Suen et al., "Clostridium argentinense, sp. nov: A Genetically Homogenous Group Composed of All Strains of Clostridium botulinum Toxin Type G and Some Nontoxigenic Strains Previously Identified as Clostridium subterminaleor Clostridium hastiforme" Int. J. System. Bacteriol. (1988) 38(4):375-381. (7 pages)
  • Van Ermengem, "Ueber einem neuen ana eroben Bacillus und seine Beziehungen zum Botulismus" Z. Hyg. Infektionskrankh. (1897) 26:1-56. An English translation can be found in A New Anaerobic Bacillus and Its Relation to Botulism, Rev. Infect. Dis. (1979) 1(4):701-719. (19 pages)
  • Koening et al., "Clinical and Laboratory Observations on Type E Botulism in Man" Medicine (1964) 43:517-545.
  • Beller et al., "Repeated Type E Botulism in an Alaskan Eskimo" N. Engl. J. Med. (1990) 322(12):855. (1 pages)
  • Schroeder et al., "Botulism from Fermented Trout" T. Norske Laegeforen (1962) 82:1084-1086. An English translation, beyond the title, is currently not available.
  • Mandell et al., eds., Principles and Practice of Infectious Diseases, 3rd Edition, Churchill Livingstone, New York, (1990) pp. 1845.
  • Brin et al., "Localized Injections of Botulinum Toxin for the Treatment of Focal Dystonia and Hemifacial Spasm" Adv. Neurol.(1988) 50:599-608.
  • Jankovic et al., "Clinical Correlates of Response to Botulinum Toxin Injections" Arch. Neurol. (1991) 48:1253-1256. (4 pages) [ISI abstract]
  • Scott, "Clostridial Toxins as Therapeutic Agents" Botulinum Neurotoxin and Tetanus Toxin, Simpson, ed., Academic Press, Inc., New York, 1989, pp. 399-412.
  • Hambleton et al., "Antitoxins and Botulinum Toxin Treatment" Brit. Med. J. (1992) 304:959-960. (2 pages) [ISI abstract]
  • "Botulinum Toxin" Lancet (1992) 304:1508-1509.
  • Lees, "Botulinum toxin: Useful in adult onset focal dystonias" Brit. Med. J. (1992) 305:1169-1170. (2 pages) Cited by 3 patents [ISI abstract]
  • Hatheway et al., "Immunogenicity of the Neurotoxins of Clostridium botulinum" Therapy with Botulinum Toxin, Jankovic et al., ed., Marcel Dekker, New York, 1993, pp. 93-107.
  • Schantz et al., "Properties and Use of Botulinum Toxin and Other Microbial Neurotoxins in Medicine" Microbiol. Rev. (1992) 56(1):80-99. (20 pages) Cited by 67 patents [ISI abstract]
  • Scott, "Antitoxin Reduces Botulism Side Effects" Eye (1988) 2:29-32. (4 pages)
  • Black, et al., "Hypersensitivity Reactions Associated with Botulinal Antitoxin" Am. J. Med. (1980) 69:567-570. (4 pages) Cited by 2 patents
  • Naik, "If the Product Becomes a Cosmetic, They Can Call It Bain de Botulism" Wall Street Journal (Nov. 6, 1992) p. B1.
  • Creasy et al., eds., Maternal-Fetal Medicine: Principles and Practice (1989) 2nd Ed., W. B. Saunders Company, Philadelphia, Pennsylvania, 613-655.
  • Kamei et al., "Establishment of Stable Mouse/Human-Human Hybrid Cell Lines Producing Large Amounts of Anti-Tetanus Human Monoclonal Antibodies with High Neutralizing Activity" Eur. J. of Epidem. (1990) 6(4):386-397. (12 pages)
  • Leary, "Gains Reported in Transferring Genetic Material to Mice" New Youk Times (Mar. 30, 1993) p. B8.
  • Mariani et al., "A New Enzymatic Method to Obtain High-Yield F(ab)2 Suitable for Clinical Use from Mouse lgG1" Mol. Immunol. (1991) 28(1/2):69-77. (9 pages) Cited by 5 patents [ISI abstract]
  • Mittendorf et al., "RH0 (D) Immunoglobulin (RhoGAM): How It Came into Being" Obstetrics and Gynecology (1991) 77(2):301-303. (3 pages) [ISI abstract]
  • Stites et al., eds., Basic and Clinical Immunology (1991) 7th Ed., Appleton & Lange, Norwalk, Connecticut, pp. 291-292, 731-737.
  • Strauss et al., "Germ Line Transmission of a Yeast Artificial Chromosome Spanning the Murine α1 (l) Collagen Locus" Science (1993) 259:1904-1907. (4 pages) Cited by 24 patents [ISI abstract]
  • Tovey, "Haemolytic Disease of the Newborn and Its Prevention" Brit. Med. J. (1990) 300:313-316. (4 pages)
  • Anderson et al., "Botulinum Toxin Treatment of Spasmodic Torticollis" Journal of the Royal Society of Medicine, (1992) 85:524-529. (6 pages) [ISI abstract]
  • Gilman et al., eds. The Pharmacologic Basis of Therapeutics (1990) 8th Ed., Pergamon Press, New York. The title page and table of contents are enclosed herewith.
  • Schwarz et al., "Botulism immune globulin for infant botulism arrives -one year and a gulf war later" The Western Journal of Medicine (1992) 156(2):197. (2 pages) Cited by 16 patents [ISI abstract]
  • Frankovich et al., "Clinical trial of botulism immune globulin for infant botulism " The Western Journal of Medicine (1991) 154(1):103. (1 pages) Cited by 17 patents [ISI abstract]
  • Berkman et al., "Clinical Uses of Intravenous Immunoglobulins" Ann. Int. Med. (1990) 112:278-292. (15 pages) Cited by 3 patents
  • McDonel, "Clostridium perfringens Toxins (type A,B,C,D,E)" Pharmacol. Ther. (1986) 10:617-655.
  • Ochs et al., "Survival of IgG Subclasses Following Administration of Intravenous Gammaglobulin in Patients with Primary Immunodeficiency Diseases" Clinical Use of Intravenous Immunoglobulins, Morell et al., eds., Academic Press, London, 1986, pp. 77-85.
  • Mankarious et al., "The Half-lives of IgG Subclasses and Specific Antibodies in Patients with Primary Immunodeficiency who are Receiving Intravenously Administered Immunoglobulin" J. Lab. Clin. Med. (1988) 112:634-640. (7 pages)
  • Smith, "Virulence Factors of Clostridium Perfringens" Rev. Infect. Dis. (1979) 1:254-260. (9 pages)
  • Lee, "Mode of Action of Cobra Venom and its Purified Toxins" Neuropoisons: Their pathophysiological actions Simpson, ed., Plenum Press, New York, 1971, pp. 21-70.
  • Greene et al., "Use of Botulinum Toxin type F injections to Treat Torticollis in Patients with Immunity to Botulinum Toxin Type A" Movement Disorders (1993) 8:479-483. (5 pages) Cited by 2 patents [ISI abstract]
  • Carruthers et al., "Treatment of Glabellar Frown Lines with C. botulinum -A Exotoxin" J. Dermatol. Surg. Oncol. (1992) 18:17-21. (5 pages) Cited by 7 patents [ISI abstract]
  • Lees et al., "Treatment of Cervical Dystonia Hand Spasms and Laryngeal Dystonia with Botulinum Toxin" J. Neurol. (1992) 239:1-4. (4 pages) [ISI abstract]
  • Vitetta et al., "Immunotoxins: Magic Bullets or Misguided Missiles?" Immunology Today (1993) 14:252-259. (8 pages) Cited by 14 patents [ISI abstract]
  • Biro et al., "In vitroEffects of a Recombinant Toxin Targeted to the Fibroblast Growth Factor Receptor on Rat Vascular Smooth Muscle and Endothelial Cells" Circ. Res. (1992) 71:640-645. (6 pages) Cited by 3 patents [ISI abstract]
  • Wawrzynczak et al., "Immunotoxins: the Power and the Glory" Immunology Today (1992) 13:381-383. (3 pages) [ISI abstract]
  • Wawrzynczak, "Systemic Immunotoxin Therapy of Cancer: Advances and Prospects" Br. J. Cancer (1991) 64:624-630. (7 pages) [ISI abstract]
  • Prior et al., "Barnase Toxin: A New Chimeric Toxin Composed of Pseudomonas Exotoxin A and Barnase" Cell (1991) 65:1017-1023. (7 pages) Cited by 11 patents [ISI abstract]
  • Zeng et al., "Radioimmunotherapy for Unresectable Hepatocellular Carcinoma Using I131 -Hepama-1 mAb: Preliminary Results" J. Cancer Res. Clin. Oncol. (1993) 119:257-259. (3 pages) [ISI abstract]
  • Burrows et al., "Eradication of Large Solid Tumors in Mice with an Immunotoxin directed Against Tumor Vasculature" Proc. Natl. Acad. Sci. USA (1993) 90:8996-9000. (5 pages) Cited by 54 patents [ISI abstract]
  • Amlot et al., "A Phase I Study of an Anti-CD22-Deglycosylated Ricin A Chain Immunotoxin in the Treatment of B-cell Lymphomas Resistant to Conventional Therapy" Blood (1993) 82:2624-33. (10 pages) Cited by 5 patents [ISI abstract]
  • Soler-Rodriguez et al., "Ricin-A-Chain and Ricin A-Chain Immunotoxins Rapidly Damage Human Endothelial Cells: Implications for Vascular Leak Syndrome" Exp. Cell Research (1993) 206:227-234. (8 pages) Cited by 7 patents [ISI abstract]
  • Pai et al., "Immunotoxin Therapy for Cancer" JAMA (1993) 269:78-81. (4 pages) Cited by 8 patents [ISI abstract]
  • Skolnick, "First Immunotoxin Therapy for Many Common Solid Tumors Enters Phase 1 Clinical Trial" JAMA (1993) 270:2280. (1 pages) Cited by 2 patents [ISI abstract]
  • Friedman et al., "Antitumor Activity of the Single-Chain Immunotoxin BR96 sFv-PE-40 Against Established Breast and Lung Xenografts" J. Immunol. (1993) 150:3054-3061. (8 pages) Cited by 9 patents [ISI abstract]
  • Wang et al., "Polyethylene Glycol-Modified Chimeric Toxin Composed of Transforming Growth Factor Alpha and Pseudomonas Exotoxin" Cancer Research (1993) 53:4588-94. (7 pages) Cited by 13 patents [ISI abstract]
  • Winter et al., "Humanized Antibodies" Immunol. Today (1993) 14:243-246. (4 pages) Cited by 37 patents [ISI abstract]
  • Green et al., "Antigen-Specific Human Monoclonal Antibodies from Mice Engineered with Human lg Heavy Light Chain YACs" Nature Genetics (1994) 7:13-21. (9 pages) Cited by 27 patents [ISI abstract]
  • Lonberg et al., "Antigen-Specific Human Antibodies from Mice Comprising Four Distinct Genetic Modifications" Nature (1994) 368:856-859. (4 pages) Cited by 38 patents [ISI abstract]
  • Rybak et al., "Humanization of Immunotoxins" Proc. Natl. Acad. Sci (1992) 89:3165-69. (5 pages) Cited by 7 patents [ISI abstract]
  • Weller et al., "Cooperative Action of the Light Chain of Tetanus Toxin and the Heavy Chain of Botulinum Toxin Type A on the Transmitter Release of Mammalian Motor Endplates" Neurosci. Letters (1991) 122:132-134. (3 pages) Cited by 2 patents [ISI abstract]
  • Olivera et al., "Conotoxins: Peptide Ligands for Receptors and Ion Channels" Toxicon. (1994) 32:244.
  • Uchitel et al., "Characterization of Calcium Channels Involved in Transmitter Release at the Mammalian Neuromuscular Junction" Toxicon (1994) 32:240-41.
  • Cull-Candy et al., "Effects of Botulinum Toxin on Neuromuscular Transmission in the Rat" J. Physiol. (1976) 260:177-203. (27 pages)
  • Kameyama et al., "Purification and Some Properties of Kappa Toxin of Clostridium perfringens" Japan J. Med. Sci. Biol. (1971) 24:9-23.
  • Matsushita et al., "Purification and Characterization of a Clostridium perfringens 120-kilodalton Collagenase and Nucleotide Sequence of the Corresponding Gene" J. Bacteriol. (1994) 176:149-56. (8 pages) Cited by 4 patents [ISI abstract]
  • Smith, "Clostridium histolyticum" The Pathogenic Anaerobic Bacteria , second edition, Charles C. Thomas, Springfield, IL, (1975) pp. 284-287.
  • Mookhtiar et al., "Clostridium histolyticum Collagenases: A New Look at Some Old Enzymes" Matrix (1992) I Supp. 1 :116-126.
  • Youle et al., "Cytotoxic Ribonucleases and Chimeras in Cancer Therapy" Critical Reviews Therapeutic Drug Carrier Systems (1993) 10:1-28. (28 pages) Cited by 6 patents [ISI abstract]


    • Inquire Regarding Licensing

    Powered by Verity
    Plaques from Patent Awards      Gallery of Obscure PatentsNominate this for the Gallery...

    Thomson Reuters Copyright © 1997-2010 Thomson Reuters 
    Subscriptions  |  Web Seminars  |  Privacy  |  Terms & Conditions  |  Site Map  |  Contact Us  |  Help